中国实用内科杂志2026，Vol.46Issue(7)：544-550,557,8.DOI:10.19538/j.nk2026070103
肿瘤治疗所致血小板减少症诊疗进展
Advances in the diagnosis and treatment of cancer therapy-induced thrombocytopenia(CTIT)
摘要
Abstract
Cancer therapy-induced thrombocytopenia(CTIT)occurs in approximately 23％-30％of solid tumors and up to half of hematologic malignancies,compromising anti-tumor treatment.Mechanisms include direct chemotherapy toxicity to megakaryocytes,immune-mediated platelet destruction(anti-platelet glycoprotein antibodies,T-cell dysregulation),and tumor microenvironment suppression.Recombinant human thrombopoietin(rhTPO)and thrombopoietin receptor agonists(eltrombopag,romiplostim,avatrombopag,hetrombopag)have demonstrated efficacy and safety.Secondary prophylaxis and combination immunomodulatory approaches(low-dose decitabine)are emerging.Individualized anticoagulation is required in special situations with concurrent thrombosis or bleeding.Further research is needed to elucidate targeted therapy-related mechanisms and develop dedicated drugs for CTIT.关键词
肿瘤治疗所致血小板减少症/化疗/血小板生成素受体激动剂/重组人血小板生成素/二级预防/免疫机制/实体瘤Key words
cancer therapy-induced thrombocytopenia/chemotherapy/thrombopoietin receptor agonist/recombinant human thrombopoietin/secondary prevention/immune mechanism/solid tumor分类
医药卫生引用本文复制引用
丁冰洁,周虎..肿瘤治疗所致血小板减少症诊疗进展[J].中国实用内科杂志,2026,46(7):544-550,557,8.基金项目
河南省自然科学基金(262300422263) （262300422263）
同心家园"医心同航"医学研究项目 （）
